INOSINE Research Study
for people with Multiple Sclerosis (Oral Therapy)

We are currently recruiting patients for the Inosine Study

Local Investigator:
Clyde Markowitz, MD at the Hospital of The University of Pennsylvania  

Purpose of the study:
The Inosine study is a research study to find out if Inosine given as an oral capsule is safe and has an effect on disease activity in patients diagnosed with Multiple Sclerosis.  Inosine is taken in a pill form.  The study will be a double-blind, placebo-controlled study.

 Study Size:
We are looking for up to 30 patients with relapsing-remitting multiple sclerosis (MS).

 Study Length:
The Inosine study will last approximately 6-8 months

 What is Inosine:

• Inosine is a dietary supplement that can be purchased in health food stores, it is a natural substance in our body
• Low levels of uric acid may be a factor that contributes to the progression of MS 
• Inosine is absorbed in the gastrointestinal tract, and turned into uric acid
• Elevated levels of uric acid in MS may be beneficial in stopping the progression

 Who Qualifies:

• Between the ages of 18-60 years old

• Patients with a diagnosis of relapsing-remitting multiple sclerosis
• No treatment within 3 months of  starting the study of:  Avonex, Betaseron, Copaxone, Novantrone, or Rebif
• Other exclusions may apply which will be determined at the beginning of the study

 Study Procedures:
Monthly visits to University of Pennsylvania will include: MRI’s, Blood draws, exams by neurologist.  Patients will be expected to take study medication 2 x’s a day on a daily basis. 

 Contact:
Tara Ordille at the Hospital of The University of Pennsylvania at: 215-662-4893